Global Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Immunotherapy, Chemotherapy), By Region - Industry Forecast 2024-2031


Report ID: SQMIG25K2005 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 36 | Figures: 74

Non-Small Cell Lung Cancer Market Competitive Landscape

  • Different techniques are being used by players to broaden their product offerings and expand their geographic reach in response to the demand for lung cancer therapies. Product innovation, alliances and partnerships, and mergers are a few of the primary tactics used by participants in the worldwide lung cancer treatments market. The major players in the market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company., Astrazeneca, Pfizer Inc., Takeda Pharmaceutical Company Limited., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim International Gmbh, Merck & Co., Inc., Celgene Corporation, Amgen Inc., Sanofi, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Allergan, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company and Astellas Pharma Inc.

Top Players in the Global Non-Small Cell Lung Cancer Market 

  • Roche
  • AstraZeneca
  • Merck & Co.
  • Bristol-Myers Squibb
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Celgene Corporation
  • Boehringer Ingelheim
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen Inc.
  • Ipsen S.A.
  • Eisai Co., Ltd.
  • Taiho Oncology, Inc.
  • Gilead Sciences, Inc.

Non-Small Cell Lung Cancer Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Non-Small Cell Lung Cancer Market size was valued at USD 23.66 billion in 2019 and is poised to grow from USD 26.94 billion in 2023 to USD 76.33 billion by 2031, growing at a CAGR of 13.9% in the forecast period (2024-2031).

Top Players in the Non-Small Cell Lung Cancer Market  'Roche', 'AstraZeneca', 'Merck & Co.', 'Bristol-Myers Squibb', 'Pfizer Inc.', 'Novartis AG', 'Eli Lilly and Company', 'Celgene Corporation', 'Boehringer Ingelheim', 'AbbVie Inc.', 'Astellas Pharma Inc.', 'Takeda Pharmaceutical Company Limited', 'Sanofi S.A.', 'GlaxoSmithKline', 'Johnson & Johnson', 'Amgen Inc.', 'Ipsen S.A.', 'Eisai Co., Ltd.', 'Taiho Oncology, Inc.', 'Gilead Sciences, Inc.'

Among the factors driving the growth of the NSCLC market are the rising rates of lung cancer caused by smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion.

The expansion of the non-small cell lung cancer treatments market is also being aided by an increase in diagnoses of non-small cell lung cancer and an increase in awareness in both developed and developing regions. The inclusion of non-small cell cancer treatments in the pipelines of leading market participants, along with increased spending by major players in research and development activities, are also propelling the market expansion internationally.

By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Non-Small Cell Lung Cancer Market

Report ID: SQMIG25K2005

$5,300
BUY NOW GET FREE SAMPLE